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Glioblastoma Multiforme (GBM, Astrocytoma grade-IV) is the most common primary malignant brain tumour 
in adults and unfortunately the most deadly. Patients with GBM exhibit a deficient anti-tumor immune 
response. Immunotherapy is rapidly becoming one of the pillars of anti-cancer therapy. GBM has not received 
similar clinical successes as of yet, a fact which may be attributed to its relative inaccessibility, its poor 
immunogenicity, or any of the many other immune mechanisms known to be inactivated in these tumor cells. 
Focused Ultrasound (FUS) is emerging as a promising treatment approach. The effects of FUS on the tissue are 
not merely thermal. Reported FUS-induced acoustic cavitation which carries both mechanical and molecular 
implications as well as FUS induced immunomodulation play important roles. This is a concise research 
highlights on a comprehensive report by the same group. We separately discuss the different pertinent 
immunosuppressive mechanisms harnessed by GBM and the immunomodulatory effects of FUS. The three 
modes of FUS action can all be assigned a molecular final common pathway of immunomodulation. Thermal 
ablation induced immune effects, microbubbles effects in disrupting the BBB and introducing antigens and 
drugs to the tumor milieu as well as FUS induced molecular effects are discussed. The effect of FUS on the 
pro-inflammatory cytokines secretion profile, the stress response, the intra-tumoral immune-cells populations, 
dendritic cells activity moderation and FUS induced increased cytotoxic cells potency are all discussed. A 
conceptual synopsis of the synergistic treatment of GBM utilizing FUS and immunotherapy is presented. The 
interaction of multiple approaches harnessing immune-components and circumventing immunosuppressing 
mechanisms may herald a new era in the fight against GBM. 
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Introduction 
Glioblastoma Multiforme (GBM, Astrocytoma grade-IV) 
is the most common primary malignant brain tumour in 
adults and unfortunately most deadly. The classical 
histological characterization of GBM is clearly becoming 
REVIEW 
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Table 1. GBM related Immune-evasion and immunosuppression mechanisms, review* 
Ref. Proposed Mechanism Comments 
27 Allelic loss of 
#10q. 
Disruption of two tumor suppressor 
genes in this locus (i.e. DBMT1, 
PTEN). 
Decreased rate of infection in 
patients with this allelic loss 
Impaired antitumor immunity and 
impaired systemic immunity 
leading to bacterial infections. 
28 PTEN and protein kinase B PTEN loss increases B7-H1 





Dominant Th2 type cytokines 
release, supporting anergy and 
tolerance to the tumor 
Tolerance and anergy to the tumor 
cells 33 PI3-K / PTEN. 
35 
p16/pRb/CDK4,  
p53/ MDM2/ p14ARF, 
EGFRvIII 
PDGF 
30 Increased Treg 
(CD4+FoxP+ T 
cells) population 
>2.5-fold increase The frequency of T-regs was shown 
to correlate directly with in vitro 
suppression of T cell activation. 
31 Increased Treg cells in TIL’s of human
GBM.




Interferon-γ Supporting development of 






tumor’s ability to down-regulate or 
express low levels of class-I MHC 




aberrant expression of this 
non-classical MHC-I molecule, 
structurally related to classical MHC 
class Ia (HLA-A, -B, -C). 
Render cells resistant to direct alloreactive lysis, and inhibits the 
alloproliferative response. 
38 Prevents efficient priming of cytotoxic T cells. 
39 Anti-Apoptosis Upregulation of anti-apoptotic proteins (i.e. Survivin), rendering cells immortal and unresponsive to normal death 
signals 
Abbreviations: PTEN - Phosphatase tensin, DBMT - Deleted brain malignant tumor, PI3-K - phosphatidylinositol 3'-kinase 
signaling pathway, EGFRvIII - Epidermal growth factor receptor variant III, PDGF - Platelet-derived growth factor receptor, 
TIL’s-Tumor Infiltrating lymphocytes. *based on Cohen-Inbar et al [1] 
less valid with respect to its prognostic significance serving 
as somewhat of a wastebasket category. Multiple molecular 
subsets of GBM are now known, carrying different 
prognostic horizons [1]. Despite standard of care treatment, 
the median survival of a patient harboring a GBM is less than 
2 years, a grim figure which changed very little in the past 
decades, proving resistant to most developments and 
revolutions incurred on modern medicine [2-4]. The unique 
nature of GBM and its inherent challenging features was 
evident as early as 80 years ago. Early reports of GBM 
patients who endured a post-operative surgical-site infection 
who surprisingly exhibited longer survival sparked an 
interest in many clinicians, suspecting an important role for 
the immune system both in disease progression as well as in 
tumor triumph. Since these initial pivotal observations, with 
developing techniques and widespread interest, multiple 
studies were put forward describing different molecular 
immunosuppressive mechanisms taking place in GBM cells 
and microenvironment, claiming these to be the dominant 
key events (table 1) [1, 5]. Unfortunately, things are not as 
straightforward or simple, and both arms of the immune 
system are known to be hampered in GBM, as do many other 
anatomical barriers, micro-environmental conditions and 
features unique to tumors within the central nervous system, 
once termed as immune-privileged [27-28]. 
Continuous-wave (CW) high intensity focused ultrasound 
(HI-FUS) is emerging as a promising treatment approach. It 
is the only noninvasive thermal technique that allows for 
real-time imaging of the treatment progress using 
MR-Thermometry [41]. Yet, the effects of FUS on the tissue 
are not merely thermal, shown to induce mechanical acoustic 
cavitation, carrying both mechanical and molecular 
implications and also modulate the host antitumor immune 
responses (table 2) [5]. We present a short report of research 
highlights capturing the essence of a paper we recently 
published [5]. We will briefly discuss different pertinent 
immunosuppressive mechanisms harnessed by GBM and the 
immunomodulatory effects of FUS.A potential conceptual 
synopsis of the two is presented. As discussed, the 
synergistic treatment of GBM utilizing HIFU and 
immunotherapy has molecular evidence to support it. For 
ease of grasping, we will divide our discussion to GBM 
immune-evasion and immune-suppressing mechanisms, 
FUS-mediated immunomodulation and a synopsis of these 
two. 
GBM mediated immune-evasion 
Mounting an effective brain anti-GBM immune response 
requires that certain requirements are met. GBM cells  
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Table 2. Focused Ultrasound Immunomodulatory effect – Literature Review 
Ref. Indication Immunologic Effect 
Mechanism Comments 









Increased TIL’sϦ, NK-cells and CD4+/CD8+ inversion. 




CD4+/CD8+ inversion and CD3+ increase in 10 patients (NP€) 
8 OS£ (6), 
HCCα (5), 
RCCβ (5) 
Increased CD4+ and inversion of the CD4+/CD8+ 
9 Choroidal 
Melanoma 
2/3 patients reverted the ratio from abnormal levels 
10 HCC Resistance 
to tumor 
re-challenge 
Increased CD4+ and inversion of the CD4+/CD8+ 




Sonicted tumor cells downregulate STAT-3 (less 
proliferation of immature DCs), decreased T-regulatory 
population in the spleen and tumor draining lymph nodes. 
13 HCC (13), 
Sarcoma (2) 
Decreased serum levels of: VEGF, TGF-β1, TGF-β2. 
14 Breast HSPπ HSP-70 and epithelial membrane antigen showed 100% 
expression in the tumor debris. 
Cytokines found in the tumor milieu: TGF-β1 (57%), 







Increased expression of HSP-72, HSP73, GRP75, GRP78 
Increased release of IL-2, IFNγ, TNFα 
Decreased release of IL-4, IL-5, IL-10 
16 CRCγ DCδ and MPSε 
activation 
ATP and HSP-60 release from CRC cells. 
DC and MPS activation (mechanical more than thermal) 
Enhanced IL-12 and TNFα secretion. 
17 HCC Increased 
CTL’sƜ 
activity 
Increased IFNγ and TNFα secretion and CTL TIL’s. 






















e The mechanical FUS effect is better than the thermal effect in 
DC activation. 
Increased CTL’s activity and IFNγ secreting cells. 
20 HCC 
21 Melanoma Increased CTL’s cytotoxicity, no increased risk of metastases 
after HIFU. 
22 Breast DCδ and MPSε 
activation 
Increased activation and infiltration of DC’s and MPS. 
Increased expression of CD80, CD86 in sonicated tumors. 
23 Melanoma 
24 NA HSPπ Peak HSP-70 expression at 6-48 hours after sonication, 




HSP-70 expression induced at a lower temperature than heat 
stress alone. 
26 Prostate (5), 
Bladder 
TCC** (4) 
HSP-27 increased expression, most notably 2-3 hours after 
sonodynamic ablation. 
The effect is still evident 5-8 days post sonication. 
ΩNumber of patients, ζNot applicable, usually refers to pre-clinical studies, ∞Neuroblastoma, *Cluster of Differentiation, €Not 
statistically Significant, £Osteosarcoma, πHeat Shock Proteins, **Transitional cell carcinoma, αHepatocellular Carcinoma, βRenal 
Cell Carcinoma, γColorectal Carcinoma, δDendritic Cells, εMononuclear phagocyte system (i.e. macrophages), ƜCytotoxic (CD8+) 
T-lymphocytes, ƩSquamous Cell Carcinoma, ϦTumor infiltrating lymphocytes. +Based on Cohen-Inbar et al [5] 
developed mechanisms to evade or block its development at 
multiple steps (Table 1) [1, 5]. Tumor associated target 
antigens must be sufficiently different from self-antigens, 
avoiding the development of immune-tolerance and anergy 
to self (and consequently to the tumor) on the one hand or the 
development of an auto-immune response on the other. 
Tumor cells must express major histocompatibility complex 
(MHC) molecule in adequate numbers to present antigens to 
Cytotoxic T-cells (CTL’s) in order to mount a specific CTL’s 
effector mediated response. The activated effector CTL’s 
should maintain their potency and activity during migration 
through involved brain parenchyma and its resident cells, as 
well as during the interaction with the tumor cells. A local 
inflammatory response should than be instigated and 
properly regulated. The multitude of immunosuppressive 
mechanisms (both active and passive) as well as 
immune-evasion techniques attributed to GBM cells are 
summarized in Table 1 [1, 5]. These mechanisms 
independently, support the evolution of anergy and tolerance 
to the tumor. Of note, the complex interplay between the 
different mechanisms stated is complex and largely 
unknown.  
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FUS-mediated immunomodulation 
FUS exerts its effect on the tumor cells utilizing three 
complementary “modes” of action: thermal ablation, acoustic 
cavitation and immunomodulation. The third mechanism 
employs the uniform low-level heating of a region of interest 
not killing the cells [14, 42-43]. The three modes of action can 
be assigned a molecular final common pathway of 
immunomodulation. Thermal ablation results in two 
complimentary effects, i.e. the release of immunogenic 
cellular antigenic debris [44] into the interstitial space 
activating Dendritic cells (DC’s) [18], as well as inducing the 
surviving tumor cells to up-regulate danger signals such as 
heat shock proteins (HSP) and adenosine tri-phosphate 
(ATP), both highly potent activators of innate immunity [16,
25, 45]. Mechanical cavitation was shown to facilitate better 
BBB penetration for drugs, antigens and immune cells as 
well as results in lysis related tumor debris [46-49]. The FUS 
microbubble (MB) induced BBB-disruption effects last 
several hours and can be localized to the tumor region, prior 
to returning to the pre-FUS state [50]. FUS-MB was reported 
to increase the intra-tumoral concentrations of delivered 
liposomal doxorubicin [51], temozolomide [52], interleukin-4 
[53], nanoparticles, DNA, plasmid vectors, and antibodies 
[54-55], and IL-12 [56]. 
Pulsed-mode FUS with increased negative pressures was 
shown to boost the systemic antitumor immune response 
through multiple mechanisms. Table 2 [5] presents a brief 
overview of key preclinical and clinical studies, per different 
tumor type, segregated based on the proposed FUS-induced 
immunomodulatory effect. FUS was shown to support and 
amplify an anti-tumor immune response, prolong overall 
survival and protect from growth of new tumors when 
re-challenged (Table 2) [5]. One should note that all 
immune-modulating effects discussed hereafter and 
presented in table-2 were described on multiple tumor types, 
not restricted to studies conducted in the CNS or on GBM 
cell lines or tissue samples. The assumption that these effects 
are tumor type independent, assigned only to FUS, were not 
validated objectively.  
FUS mediated immune effects can be grouped into its 
effects on cytokines and the stress response, its effects on 
peripheral and intra-tumoral immune cell populations, FUS 
mediated augmentation of Dendritic cell activity or a more 
general, increased CTL’s potency and FUS mediated 
resistances to tumor re-challenge. The latter refers to 
lengthened survival and immunomodulatory effects of FUS 
noted in different reports but lacking a proven exact 
molecular mechanism [11, 20, 23]. HSP’s are known potent 
immune-stimulants, able to bind tumor peptide antigens and 
enhance tumor cell immunogenicity [57-62]. FUS was shown 
to up-regulate the expression of HSP70 both in-vitro and 
ex-vitro [16, 24, 25]. An increased HSP-70 expression was 
detected on the surviving cell membrane of 23 patients with 
breast cancer treated with HIFU ablation[14] FUS was shown 
to enrich the TIL’s population in immune-potent 
pro-inflammatory potent anti-tumor effector cells in human 
breast cancer specimens [6, 63], posterior uveal melanoma [9], 
pancreatic carcinoma [7], osteosarcoma [8], hepatocellular 
carcinomas (HCC) [8], and Renal Cell Carcinoma (RCC) [8]. 
FUS was shown to enhance the infiltration capabilities and 
activity of dendritic cells (DCs) [36, 40] as well as other antigen 
presenting cells [22] in the treated tumor, leading to an 
increased expression of costimulatory molecules and 
enhanced secretion of IL-12 (via DCs) and TNF-α 
(macrophages) [16]. Zhang et al [20] demonstrated that tumor 
debris induced by FUS could serve as an effective 
immunogenic vaccine. Increased CTL’s Potency and effector 
function after FUS, reported as increased IFNγ and TNFα 
secretion [17-19] or increased direct CTL’s mediated 
cytotoxicity [21] serves as another avenue of 
immunomodulation. 
Synopsis& Future directions 
The complexity of interacting immune-evasion and 
immunosuppressing mechanisms dysregulated in GBM cells, 
mechanisms modulated by FUS, as well as tumor specific 
and patient (i.e. immune system) specific mechanisms is 
largely unknown. A theoretical action-reaction scheme is 
presented in previous comprehensive report [5]; connecting 
certain known GBM-evasion mechanisms with the FUS 
induced counter response. One should note that a single FUS 
mediated effect may influence multiple immune mechanisms 
and vice versa. There seem to be a theoretical basis for the 
effectiveness of FUS immunomodulation, synergistically 
supporting various immunotherapeutic approaches in 
overcoming many of the GBM mediated immune-resistance 
mechanisms. Future research still needs to be done to both 
dissect the different FUS-induced molecular and 
immunological mechanisms at play as well as to optimize the 
FUS treatment method. 
Conclusions 
No single treatment modality will cure GBM. In recent 
years, immunotherapy has come to the forefront of 
anti-cancer therapy. While some cancer types have been 
amenable to immunotherapeutic approaches, GBM has not 
received similar clinical successes, likely due to its poor 
immunogenicity and for its location in the immunologically 
distinct CNS. We briefly review FUS-induced 
immunomodulation, which can be harnessed to current and 
developing immunotherapies approaches. These research 
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highlights of a broader report by our group[5] serve to better 
define the essence of new findings and existing gaps in our 
understanding. Further study to the synergistic collaboration 
of different therapeutic approaches and the elaborate 
molecular immune interplay will shed light on this 
formidable challenge. 
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